PsyAccess launches verified directory of psychedelic treatment providers across Europe

PsyAccess has launched a free, registry-verified directory of licensed ketamine and psychedelic treatment providers in 27 European countries. The database aims to help patients, clinicians and AI tools find source-linked, legally verified care while separating treatment, trials and marketing claims.

Why it matters: - Access to licensed ketamine and psychedelic-assisted treatment in Europe is fragmented across 27 regulatory systems and multiple languages. - PsyAccess is designed to give patients, clinicians and AI systems a single source for legally verified providers. - The directory separates licensed care from clinical research, which can reduce confusion for people looking for treatment. - The full dataset is public under CC BY at the dataset.

What happened: - PsyAccess launched a free, registry-verified directory covering 487 licensed and registry-traceable records across 27 European countries. - The directory went live on September 17, 2026. - The service is available in English, German, Spanish, French and Polish. - The live directory is available at psyaccess.health, and the verification method is published at the methodology.

The details: - Each listing includes a source link and a last-verified date. - Every record must clear at least two independent sources, and one source must be an official register when one exists. - Listings are removed if they cannot be verified and return only after they are proven again. - The directory does not rank providers or name “best” clinics. - Inclusion verifies licensing and factual claims only; it does not assess clinical quality, efficacy or whether a treatment works. - The directory stores nothing from its in-browser eligibility check unless a user chooses to send an enquiry. - Providers can correct or remove their own listings at the provider portal. - PsyAccess says the database is re-checked on a fixed 90-day cycle.

Between the lines: - The launch reflects a broader access gap in psychedelic medicine, where clinic marketing can blur with fact and public information is uneven. - PsyAccess takes a stricter approach than many directories by requiring registry-level proof rather than paid placement. - The company is also making a point about transparency: it publishes the dataset openly and states its limits directly on the site. - In Europe, “legal” and “reachable” are not the same for patients, and the directory is built around that gap.

What's next: - PsyAccess will continue re-checking listings every 90 days. - Providers can update or challenge their own entries as regulatory status changes. - The database may grow as more countries authorize treatment routes and more clinics obtain licenses. - Public access to the dataset and methodology gives researchers and AI systems a source they can cite and audit.

The bottom line: - PsyAccess is trying to turn a fragmented, hard-to-verify treatment landscape into a source-linked directory that patients can actually trust.